EUVIMEDEUVIMED entdecken
Crossref

Sleep as an Active Modifier of Blood-Based Biomarkers in Alzheimer’s Disease

Yoo Hyun Um

Sleep Medicine Research · 31.03.2026 · 17 (1) · 1-2

DOI: 10.17241/smr.2026.03384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sleep Medicine Research, erschienen am 31.03.2026. Verfasst von Yoo Hyun Um. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blood-based biomarkers (BBMs) for Alzheimer’s disease (AD), including phosphorylated tau at threonine 217, 181 (pTau217, pTau181), the amyloid-β 42 to amyloid-β 40 ratio (Aβ42/40), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), are emerging as a cost-effective platform for early screening and detection. Increase in relevant research is grounded in the assumption that plasma biomarkers primarily reflect stable, pathology-driven brain processes. However, emerging evidence suggests that diverse demographic factors and clinical comorbidities can influence BBM levels [1]. One of them is sleep, not merely a behavioral state but a powerful biological modulator of protein clearance, neuroinflammation, and brain-blood transport [2,3]. For this reason, I propose that sleep should be conceptualized as an active modifier of BBMs, as interpretations that do not account for sleep may lead to misclassification, particularly in preclinical disease where biomarker changes are subtle. Although BBMs are often viewed as highly stable indicators, accumulating findings suggest they are sensitive to sleep-related processes. A recent study demonstrated that disrupted rest-activity rhythm in midlife women has been linked to poorer processing speed and higher plasma phosphorylated tau at threonine 231 (p-Tau231) levels. Moreover, poorer sleep quality was associated with higher plasma p-Tau231 levels and interacted with AD ge-netic risk to influence p-Tau231 concentrations [4]. Sleep disorders such as obstructive sleep apnea (OSA) also affected the BBM levels, with blood total Aβ, Aβ42, Aβ40, and total tau all elevated in OSA patients [5]. Furthermore, p-Tau217 was

Zitieren

APA

Um, Y. H. (2026). Sleep as an Active Modifier of Blood-Based Biomarkers in Alzheimer’s Disease. Sleep Medicine Research, 17(1), 1-2. https://doi.org/10.17241/smr.2026.03384

Vancouver

Um YH. Sleep as an Active Modifier of Blood-Based Biomarkers in Alzheimer’s Disease. Sleep Medicine Research. 2026;17(1):1-2. doi:10.17241/smr.2026.03384

BibTeX
@article{Um2026,
  author = {Um, Yoo Hyun},
  title = {Sleep as an Active Modifier of Blood-Based Biomarkers in Alzheimer’s Disease},
  journal = {Sleep Medicine Research},
  year = {2026},
  volume = {17},
  number = {1},
  pages = {1--2},
  doi = {10.17241/smr.2026.03384}
}
Kostenlos starten →